



Cite this: *Nanoscale Adv.*, 2023, 5, 4758

## Regulating the surface topography of CpG nanoadjuvants *via* coordination-driven self-assembly for enhanced tumor immunotherapy†

Li Zhang,<sup>‡abc</sup> Lingpu Zhang,<sup>‡d</sup> Yuqi Wang,<sup>e</sup> Kai Jiang,<sup>e</sup> Chao Gao,<sup>e</sup> Pengfei Zhang,<sup>b</sup> Yujie Xie,<sup>ID f</sup> Bin Wang,<sup>d</sup> Yun Zhao,<sup>a</sup> Haihua Xiao,<sup>ID \*d</sup> and Jie Song,<sup>ID \*be</sup>

Immunoadjuvants play a key role in enhancing the efficacy of therapeutic tumor vaccines for treating malignant and recurrent cancers. However, due to the bottleneck in the rational design and mechanistic understanding of novel adjuvants, currently available immunoadjuvants in clinical practice are very limited. To boost adjuvant design and development, herein we propose a surface topography regulatory strategy for constructing novel adjuvants with improved adjuvant properties. One of the licensed adjuvants with a well-defined molecular mechanism of immune activation, cytosine–phosphate–guanine oligodeoxynucleotides (CpG ODNs), was used as the material framework. We constructed immunostimulatory CpG nanoparticles (CpG NPs) with different surface topographies by coordination-driven self-assembly between CpG ODNs and ferrous ions. These self-assembled CpG NPs combine the biological and physical activation abilities of innate immunity and can be used as adjuvants of tumor antigens for malignant tumor immunotherapy. The experimental results showed that these CpG NPs could rapidly enter innate immune cells and remodel the tumor microenvironment (TME) to enhance anti-tumor immunotherapy *via* (i) inducing proinflammatory cytokine production; (ii) promoting the transformation of macrophages from immunosuppressed M2 types into immunoactivated M1 types; (iii) amplifying the antigen presentation of mature dendritic cells (DCs), and (iv) activating T cells in tumor sites. Among the prepared nanostructures, pompon-shaped nanoparticles (NP<sup>PO</sup>) showed the strongest adjuvant properties and anti-tumor immunotherapeutic effect as the adjuvant of ovalbumin in melanoma-bearing mice. Overall, this work provides an effective strategy for designing novel adjuvants for activating the immunosuppressed TME to enable better cancer immunotherapy.

Received 11th May 2023  
Accepted 9th July 2023

DOI: 10.1039/d3na00322a  
[rsc.li/nanoscale-advances](http://rsc.li/nanoscale-advances)

### 1. Introduction

Tumor immunotherapy has revolutionized traditional cancer therapies and made remarkable clinical advances in recent years. As a new type of effective tumor immunotherapy, therapeutic tumor vaccines can activate or enhance the anti-tumor

immune response of the body by expressing specific tumor antigens and then killing and eliminating tumor cells under the assistance of immunoadjuvants, showing great application prospects in the treatment of malignant tumors.<sup>1–3</sup> Most tumor vaccines consist of one or more tumor antigenic components and immunoadjuvants that enhance the magnitude, breadth, and durability of the antigenic immune response.<sup>4–6</sup> Therefore, immunoadjuvants are key components in improving vaccine effectiveness. However, due to safety concerns as well as the difficulties in the research of adjuvant design and immunologic mechanisms, the development of new adjuvants is very slow.<sup>7–9</sup> Clinically approved adjuvants are far from meeting the needs of tumor therapy and vaccine development. Consequently, developing new, novel immunoadjuvants with high safety, excellent properties and a clear immunologic mechanism is of great significance for the development of therapeutic tumor vaccines and the immunotherapy of malignant tumors.

Cytosine–phosphate–guanosine oligodeoxynucleotides (CpG ODNs) are one of the clinically licensed adjuvants with a well-defined molecular mechanism of immune activation, attracting extensive attention and continuous research in the field of

<sup>a</sup>School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang 310024, China

<sup>b</sup>Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China

<sup>c</sup>School of Pharmacy, Changzhou University, Changzhou, Jiangsu 213164, China

<sup>d</sup>Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China

<sup>e</sup>Institute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China. E-mail: [jie@sjtu.edu.cn](mailto:jie@sjtu.edu.cn)

<sup>f</sup>School of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3na00322a>


‡ These authors contributed equally to this work.

immunotherapy.<sup>10–13</sup> They can be recognized by toll-like receptor 9 (TLR-9) on endo/lysosomal membranes and induce the production of pro-inflammatory cytokines to successively activate both innate and adaptive immunity.<sup>14,15</sup> However, owing to structural instability in the complex tumor microenvironment (TME), CpG adjuvants are currently only approved for hepatitis B and SARS-CoV-2 vaccines and not for tumor vaccines.<sup>16,17</sup> Thus, in order to broaden their application, researchers have focused on improving the structural stability and prolonging the half-life of CpG ODNs through skeleton modification, protein/peptide binding or nanoparticle preparation.<sup>18–21</sup> Nanoparticulate adjuvants have the advantages of enhancing the immune response and reducing tolerance owing to their characteristics of small size and large specific surface area.<sup>22,23</sup> With the in-depth study of nanoadjuvants, researchers found that the surface topography of nano-adjuvants can influence the adsorption of antigens and adhesion with immune cells and is another key factor in determining the efficacy of nanoadjuvants in addition to the composition and particle size.<sup>24–26</sup> Thus, constructing CpG-based nanoparticles (CpG NPs) with desirable surface topography is an effective approach to improve the structural stability of CpG ODNs and enhance their adjuvant properties.

Emerging evidence indicates that nanoadjuvants with special surface topographies have unique performance advantages.<sup>27,28</sup> Previous studies have reported that a gold nanostar adjuvant system with surface modification of CpG ODNs showed deep tumor penetration ability, induced a cascade immune response and significantly inhibited tumor growth.<sup>29–31</sup> Compared to spheroidal nanostructures that accumulated mostly in the center of the endosome, star-shaped nanostructures accumulated primarily along the interior edges, which achieved a higher level of toll-like receptor 9 (TLR9) activation along with the enhanced secretion of pro-

inflammatory cytokines and chemokines.<sup>32</sup> Another study found that the nanospiky surface of TiO<sub>2</sub> microparticles can activate and amplify the innate immune response by placing mechanical stress on the cells, stimulating potassium efflux and inflammasome activation during the phagocytosis of immune cells.<sup>27</sup> These findings indicate that increased surface roughness of nanoadjuvants contributes to enhanced immune activities, thereby advancing our understanding of the mechanisms by which surface topography modulates immune responses. However, these nanoadjuvants were fabricated based on rigid nanoparticles and may have a significant impact on immune responses. Therefore, the structure–activity relationship between surface topography and immune activity of CpG-framed nanoadjuvants still needs to be explored.

To understand the immunomodulatory capacity of surface topographies of nanoadjuvants on immune cells for cancer therapy, we designed a series of specific surface topographies on self-assembled CpG nanoparticles (CpG NPs) ranging from smooth to short plush to plush and finally to a spiky surface. They were named spherical, urchin-, pompon- and burr-shaped nanoparticles and denoted as NP<sup>sp</sup>, NP<sup>ur</sup>, NP<sup>po</sup> and NP<sup>bu</sup> for short, respectively (Scheme 1A). Due to the combination of physical and biological cues, the designed CpG NPs are believed to be able to modulate innate immune responses of the TME for enhanced anti-tumor immunotherapy. First, we tested the cytotoxicity, cellular uptake behavior and subcellular distribution of different nanostructures in RAW264.7 macrophages. Then, the polarization of macrophages and maturation of dendritic cells on different nanostructures were systematically examined by the evaluation of cytokine secretion and cell surface marker expression (Scheme 1B). Last, we assessed the anti-tumor efficacy and immunosuppressive TME activation of the obtained CpG NPs on a melanoma animal model by



**Scheme 1** Schematic illustration of the designed CpG nanoparticles with different surface topographies for amplifying innate immune responses and enhancing cancer immunotherapy. (A) The coordination-driven co-assembly process of CpG oligodeoxynucleotides and ferrous ions to synthesize CpG nanoparticles. (B) Schematic of the designed nanostructures applied to activate innate immune cells and amplify immune responses. (C) Schematic of the designed nanostructures used as an immunologic adjuvant to assist tumor antigens to enhance cancer immunotherapy for melanoma.



combining them with tumor model antigen ovalbumin (OVA) (Scheme 1C).

## 2. Experimental section

### 2.1. Preparation and characterization of CpG NPs

Inspired by the one-pot synthesis method reported by Li's team,<sup>33,34</sup> we adopted a similar method to prepare CpG NPs with different surface topographies. Concretely, for the preparation of spherical CpG NPs, 10  $\mu$ L CpG aqueous solution (100  $\mu$ M) and 8  $\mu$ L FeCl<sub>2</sub> aqueous solution (50 mM) were first added into 82  $\mu$ L pure water in a 200  $\mu$ L PCR tube, immediately followed by a quick vortex to make sure all the ingredients mixed thoroughly. Next, the mixture was allowed to stand at 95 °C for 2 h. Finally, the product was obtained by cooling it to room temperature. The other three CpG NPs were prepared in double distilled water and Tris-HCl buffer solution (20 mM, pH = 7.4) supplemented with 10 mM MgCl<sub>2</sub>, respectively. The concentrations of CpG strands and FeCl<sub>2</sub> in the reaction system are shown in Table S1.† The total volume of the reaction system was set at 100  $\mu$ L.

The product solution was deposited on a carbon-coated copper grid and subjected to TEM imaging (120 kV) and SEM imaging (2 kV) to characterize the surface topography. The hydrodynamic size and distribution of the prepared nanoparticles were measured by dynamic light scattering on a Zetasizer Nano ZS instrument (Malvern, UK). The characteristic absorption spectra of free CpG ODN solution and the above assembly solution were measured using a circular dichroism spectrometer in a heating process (25–95 °C) and a thermostatic process (95 °C) for 2 h, respectively.

### 2.2. Cell culture

RAW264.7 cells and Hacat used in the experiments were purchased from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were cultured in high-glucose DMEM supplemented with 10% FBS and 1% P/S in a 5% CO<sub>2</sub>, 37 °C incubator. BMMs were prepared by culturing mouse bone-marrow cells isolated from Balb/c mice with a 100 ng mL<sup>-1</sup> macrophage colony-stimulating factor (Biologen) in a cell culture medium for 7 d. BMDCs were prepared by culturing bone-marrow cells from Balb/c mice with 10 ng mL<sup>-1</sup> of granulocyte-macrophage colony-stimulating factor (Biologen) in a cell culture medium for 7 d. BMDCs were also sorted on a high-speed cell sorter based on DC marker CD11c on a BD FACSAria. All the procedures and experiments were performed in an endotoxin-free environment.

### 2.3. MTT assays

Cells were seeded in 96 well plates at 1  $\times$  10<sup>4</sup> cells per well for 12 h and then were cultured with free CpG, free FeCl<sub>2</sub> and CpG NPs at a series of CpG concentration gradients (0–10 000 nM) for 24 h. To the cells, 20  $\mu$ L of MTT in PBS solution (2 mg mL<sup>-1</sup>) were added and incubated for 4 h at 37 °C. After incubation, the medium was removed and 100  $\mu$ L dimethyl sulfoxide was added to completely dissolve formazan. Finally, the absorbance was

measured using a microplate reader (Tecan, Switzerland) at a wavelength of 570 nm to calculate the cell survival rate. The values represented the mean  $\pm$  SD of 5 replicates and were plotted relative to the untreated cells.

### 2.4. Live/dead assays

To further determine cell viability, RAW264.7 cells were incubated with free CpG, free FeCl<sub>2</sub> and CpG NPs at a dose of 1 nmol sample per well (CpG equivalent of 1000 nM) for 24 h. After the indicated times of treatment, cells were stained with calcein-AM to identify live cells (green fluorescence) and ethidium homodimer to exclude dead cells (red fluorescence). The results were analyzed by fluorescence microscopy (CSU-W1-SoRa, Nikon).

### 2.5. Cellular uptake studies

RAW264.7 cells were cultured on a glass-bottom plate for 24 h, and then the FAM-labeled free CpG and CpG NPs were added and incubated with cells (CpG equivalent of 1000 nM) for 4 h in the experiments. The cell nucleus was stained with Hoechst 33 258 and imaged with a confocal fluorescence microscope (CSU-W1-SoRa, Nikon). To quantify the cellular uptake efficiency, flow cytometry (CytoFLEX LX, Beckman Coulter) was used to determine the green fluorescence intensity (corresponding to the amount of free CpG or CpG NPs) in each cell.

### 2.6. Intracellular distribution of CpG NPs

RAW264.7 cells were seeded in a 4-chamber glass plate at a density of 1  $\times$  10<sup>4</sup> cells per well and subsequently incubated with FAM-labeled CpG NPs (CpG equivalent of 1000 nM) for 0.5, 1, 2, 4 and 6 h at 37 °C. After rinsing with PBS buffer 3 times, cells were fixed with paraformaldehyde for 15 min. The fixed cells were washed with PBS buffer 3 times and subsequently stained with a 1 : 1.5 mixed solution of Hoechst 33 258 (20  $\mu$ g mL<sup>-1</sup>) and Lysotracker Red DND-99 (100 nM) for 40 min at 37 °C. Finally, the above cells were observed using a fluorescence microscope fitted with the correct filter set. Multiple fluorescence images were collected from each sample group at each time point for co-location parameter analysis. Co-localization parameters were analyzed using the NIS-Elements analysis software. To comprehensively display the fluorescence distribution in cells, single cells in each test group were selected for multi-layer scanning to obtain Z-stack images (step size, 1  $\mu$ m).

### 2.7. Gene profiling

RAW264.7 macrophages were first incubated in a 24-well plate with a density of 2  $\times$  10<sup>4</sup>. After cells adhered to the wall, culture media were replaced with IL-4 containing culture media with a concentration of 10 ng mL<sup>-1</sup>. After 20 h, free CpG, FeCl<sub>2</sub> solution and CpG NPs were added to the cell culture media at a dose of 1 nmol CpG strands per well and a dose of 400 nmol FeCl<sub>2</sub> solution. After another 20 h, mRNA in the cells was collected for reverse transcription and amplification with real-time qPCR analysis. Expressions of genes related to M1 and M2 macrophage subtypes were analyzed by quantitative real-time RT-PCR using the indicated primers in Table S3.† The



data are presented as the fold change in gene expression normalized to an endogenous reference gene and relative to the untreated control.

### 2.8. Cell-surface marker analysis

Cell surface markers were analyzed by flow cytometry (BD FACSAria). To this end, BMDCs were cultured with free CpG,  $\text{FeCl}_2$  solution and CpG NPs for 12 h. The cells were collected and stained with anti-MHC-II (25-9-17, 1 : 200), anti-CD40 (3/23, 1 : 100), anti-CD80 (16-10A1, 1 : 100) and anti-CD86 (GL-1, 1 : 100) antibodies. All the antibodies were obtained from Biologend. The stained cells were fixed, quantified by flow cytometry and analyzed with FlowJo software.

### 2.9. Animals

Balb/c mice were obtained from Beijing National Laboratory for Molecular Sciences and housed on a 12 h day/12 h night schedule (lights on from 19:00 to 07:00) at a constant temperature ( $22 \pm 1^\circ\text{C}$ ) and humidity (60%). Studies were approved by the Animal Care and Use Committee at the Institute of Chemistry, Chinese Academy of Sciences (No. 2022R0004). All the animals received humane care and every effort was made to minimize suffering in compliance with institutional and National Institutes of Health guidelines.

### 2.10. Anti-tumor efficacy test

Balb/c mice (6 weeks, half male and half female) were subcutaneously inoculated with B16-OVA cells for tumor modeling first. After 7 days, the tumor-bearing mice were intramuscularly injected with PBS, free CpG, free  $\text{FeCl}_2$ , and four types of CpG NPs (1.32 mM  $\text{FeCl}_2$  solution for free  $\text{FeCl}_2$ , CpG equivalent of 3.3  $\mu\text{M}$  for free CpG and CpG NPs) combined with OVA. The injection was given every 4 days for a total of 4 injections. Tumor volumes were monitored on days 0, 2, 4, 7, 10 and 14. After a 14-day test, ratios of the tumor-infiltrating mature DCs (CD80 and CD86), activated T cells (CD3 and CD8) and NK cells (KLRG1 and CD69) in melanoma in different treatment groups were detected by flow cytometry.

### 2.11. *In vivo* biosafety evaluation

Balb/c mice (6 weeks, half male and half female) were intramuscularly injected with PBS, free CpG, free  $\text{FeCl}_2$ , or self-assembled CpG NPs at an equivalent dose of CpG strands (10  $\mu\text{g}$  per mouse). The injection amount is 1.32 mM  $\text{FeCl}_2$  solution for free  $\text{FeCl}_2$  and 3.3  $\mu\text{M}$  equivalent CpG for free CpG and CpG NPs in 100  $\mu\text{L}$  solution, respectively. The body weight of mice was monitored on days 1, 4, 6, 8 and 10. After 10 days, the mouse spleens were taken out, photographed and weighed. Then, the removed spleens were ground and utilized for parameter detections, including CD11b, CD80, and CD86 secreted from DCs and CD3, CD4, CD8, CD44, CD62L, and IFN- $\gamma$  from T cells. The results were analyzed with flow cytometry and FlowJo software.

### 2.12. Statistics and reproducibility

A two-tailed *t*-test was used to analyze the difference between sample and PBS groups, and a one-way analysis of variance (ANOVA) among multiple groups with a confidence interval of 95%. All the data are presented as the mean  $\pm$  s.d. as indicated in the experiments. *P* values were calculated using PRISM software (GraphPad) and regarded as significant if less than 0.05. No animals were excluded from the analysis.

## 3. Results and discussion


### 3.1. Preparation and characterization of CpG NPs

CpG NPs were fabricated *via* a one-pot synthesis method based on the co-assembly of CpG ODNs and ferrous ions. Briefly, the solution of CpG ODNs and  $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$  was intensively mixed, heated to 95  $^\circ\text{C}$  and left for 2 h, and then cooled to room temperature to obtain the assembled CpG NPs. Various surface topographies were obtained *via* the regulation of the concentration of assembly materials and the ionic strength of the assembly solvent (Table S1†). We hypothesize that this is due to a corresponding adjustment in the competition and balance of intermolecular forces between the DNA-DNA base complementary pairing and the ferrous ion-DNA coordination.<sup>35,36</sup>

Fig. 1A and B show the surface topography of different samples under transmission electron microscopy (TEM) and scanning electron microscopy (SEM). The diameter distribution of the obtained CpG NPs measured from the TEM results was shown in Fig. 1C, which was  $169 \pm 35$  nm ( $\text{NP}^{\text{SP}}$ ),  $114 \pm 22$  nm ( $\text{NP}^{\text{ur}}$ ),  $217 \pm 30$  nm ( $\text{NP}^{\text{PO}}$ ), and  $325 \pm 65$  nm ( $\text{NP}^{\text{bu}}$ ), respectively. Fig. 1D shows the dynamic light scattering (DLS) results. Hydrodynamic diameters ( $D_h$ ) and polydispersity indices (PDIs) of the CpG NPs in ultrapure water were measured as 173 nm (0.20), 132 nm (0.39), 168 nm (0.55), and 216 nm (0.26), respectively (Table S2†). Hence, the obtained CpG NPs have similar sizes ( $\sim 200$  nm) and relatively narrow size distributions in an aqueous solution. Zeta potential measurement shows that the CpG ODNs were negatively charged while all the CpG NPs were positively charged (Fig. S1†). Furthermore, to test the structural stability of these nanoparticles in aqueous solutions, we tracked their size changes in ultrapure water and PBS buffer. As shown in Fig. S2,† CpG NPs retained their nanoscale diameters after 7 days of room temperature storage in both solutions.

Meanwhile, we monitored the conformational transformation of CpG ODNs during the co-assembly process using circular dichroism (CD) spectroscopy. Free CpG solution showed two negative CD signals at 210 and 250 nm and two positive signals at 220 and 275 nm (Fig. S3A†), which correspond to the characteristic absorption peaks of B-DNA conformation.<sup>37,38</sup> With an increase in temperature (from 25  $^\circ\text{C}$  to 95  $^\circ\text{C}$ ), the signal intensity of circular dichroism decreased gradually, but there was no deviation. The characteristic absorption peaks of CpG ODNs were retained in the mixed solution of CpG ODNs and ferrous ions, but the peak intensity dropped to negative values. With an increase in temperature of the mixed solution, the signal intensity decreased continuously, and splits and deviations occurred (Fig. S3B†). This was believed to be





**Fig. 1** Characterization of four structural DNA nanoparticles. (A) TEM images and (B) SEM images of the four structural DNA nanoparticles. Scale bar: 200 nm. (C) Diameter distribution of DNA nanostructures measured from TEM images. (D) Hydrodynamic diameter distribution of DNA nanostructures in an aqueous solution measured by DLS.

caused by the formation of CpG NPs and the reduction of free CpG ODNs. The corresponding ultraviolet-visible spectral results also showed the structural transformation of CpG ODNs and confirmed the successful co-assembly of CpG NPs.


### 3.2. Cytotoxicity, cellular uptake and subcellular distribution of CpG NPs

To explore the safe dose of CpG NPs for driving an anti-cancer immune response, we tested the cytotoxicity of CpG NPs toward RAW264.7 macrophages and human immortalized keratinocytes (Hacat). First, RAW264.7 macrophages were incubated with a gradient concentration (0–10 000 nM) of free CpG, free FeCl<sub>2</sub> and CpG NPs for 24 h. As shown in Fig. S4A,† macrophage viability decreased along with an increase in the sample concentration. Over 90% of RAW264.7 macrophages survived in all test groups at relatively low dosages (<500 nM) of equivalent CpG strands; over 75% of cells survived even at the higher dosage (2000 nM) of equivalent CpG strands. Subsequently, we tested the viability of Hacat incubated in the gradient concentration (0–2000 nM) of the above samples. Similarly, Hacat viability decreased slowly with an increase in

the sample concentration, and the cell survival rate was more than 75% at a maximum concentration of 2000 nM (Fig. S4B†). According to these results, we adapted 1000 nM equivalent CpG strands, where cell activity was more than 80% in all sample groups, for the following cellular uptake and immune activation experiment. Fig. S4C† shows the live/dead cell-staining fluorescence images of RAW264.7 macrophages after incubation with CpG NPs at CpG equivalent 1000 nM for 24 h. The proportion of living cells in all sample groups was above 90% except for the pompon-shaped nanostructure (NP<sup>po</sup>), further confirming the safety of the selected dose of CpG NPs.

Cellular adhesion and internalization are the initial steps in immune cell activation by CpG NPs. To understand the effect of surface topography on the interaction between NPs and immune cells, the cellular uptake efficiency of CpG NPs in RAW264.7 macrophages was examined by confocal laser scanning microscopy (CLSM) and flow cytometry. First, 6-carboxy-fluorescein (FAM) labeled CpG ODNs were used to prepare fluorescent CpG NPs. Then, RAW264.7 macrophages were exposed to CpG ODNs/NPs in a serum culture medium at a safe dosage of 1000 nM for 4 h. As shown in Fig. 2A and S5,† FAM-





**Fig. 2** Cellular uptake and subcellular distribution in macrophages of the four structural DNA nanoparticles. (A) Representative confocal fluorescence images of RAW264.7 cells treated with free CpG and CpG NPs (CpG equivalent of 1000 nM) for 4 h. CpG strands were labeled with FAM (green), and RAW264.7 cells were stained with Hoechst (blue). Scale bar: 20  $\mu$ m. (B) Flow cytometry analysis of the cellular uptake efficiency of free CpG and CpG NPs after 4 h of incubation. (C) Flow cytometry quantification of the DNA NP uptake by RAW264.7 cells after 4 h of incubation ( $n = 3$ ). Mean fluorescence intensity of the corresponding results in flow cytometry analysis. (D) Z-stack images at 45° view (step size, 1  $\mu$ m) of cells incubated with different NPs for certain times (0.5, 1, 2, 4 and 6 h), followed by staining with either Hoechst (blue) or Lysotracker (red). Scale bar: 10  $\mu$ m. (E) Pearson co-localization analysis of samples with Lysotracker at different incubation times in (D). Pearson's correlation coefficients were calculated with NIS-Elements analysis software. Error bars were obtained by analysis of multiple cells. (F) Mander's overlap of different NPs with Lysotracker at 4 h which was calculated using the percentage of overlapped fluorescent pixels. Statistical analysis was performed using a one-way analysis of variance (ANOVA) comparison. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , and \*\*\*\* $p < 0.0001$ .

labeled CpG ODNs/NPs (green fluorescence) were both observed to accumulate within cells after 4 h of incubation. To quantitatively estimate the amount of sample uptake by cells, we used flow cytometry to measure the fluorescence intensity of intracellular FAM labels. Fig. 2B and C show the mean fluorescence intensity of the internalized samples after 4 h of incubation, which are 914, 921, 24 132, 27 848, 37 865 and 14 366, respectively. Notably, NP<sup>po</sup> exhibited the highest fluorescence

intensity among the four CpG NPs, revealing that NP<sup>po</sup> significantly increased the cellular uptake efficiency of CpG ODNs. We speculated that NP<sup>po</sup> has the optimal specific surface area for cell adhesion and cell uptake. Furthermore, we used NanoLive to observe the real-time cellular uptake behaviors of CpG NPs by capturing a picture every 30 seconds within 2 h. To display the cell uptake process, we next integrated them into a video with 6 frames per second. As shown in Video S1 and S2,† we found that

a non-spherical surface structure is more likely to cause the deformation and phagocytosis of macrophages. Together, the self-assembled CpG NPs with desirable surface topography can successfully improve the cellular uptake efficiency of CpG ODNs.

Previous studies have demonstrated that CpG ODNs can be recognized by toll-like 9 receptors (TLR9) on endo/lysosomal membranes after internalization and induce a cascade immune response.<sup>39,40</sup> To understand how the self-assembled CpG NPs affect TLR9 recognition to activate immunity, we

next tracked their subcellular distributions by CLSM. As depicted in Fig. 2D and S7,† the green fluorescence intensity of FAM-labeled CpG strands increased with the extension of the incubation time of cells in samples. The overlap between FAM-labeled CpG NPs (green) and LysoTracker-labeled lysosomes (red) also changed with incubation time. To quantitatively analyze the association between CpG NPs and lysosomes, Pearson's correlation and Manders' overlap between them were analyzed using the NIS-Elements analysis software (Fig. S8†). As shown in Fig. 2E, Pearson's correlation values of samples




Fig. 3 *In vitro* immune responses of macrophages and DCs on various nanostructures. (A and B) Cytokine secretion by RAW264.7 cells with different treatments. (A) The relative gene expression of RAW264.7 cells induced by free CpG, free FeCl<sub>2</sub>, and four structural CpG NPs (CpG equivalent of 1000 nM) for 20 h. The mRNA levels of M1 markers (TNF- $\alpha$  and IL-12b) were analyzed by the quantitative reverse transcription-polymerase chain reaction (qRT-PCR). (B) The relative gene expression of RAW264.7 cells that were pre-induced by IL-4 (10 ng mL<sup>-1</sup>) for 20 h and then induced by free CpG, free FeCl<sub>2</sub>, and CpG NPs for another 20 h. mRNA levels of M2 markers (Arg-1 and Mrc-1) and M1 markers (TNF- $\alpha$  and IL-12b) were first normalized to ACTB and then normalized to untreated controls. The data are shown as mean  $\pm$  SD ( $n = 3$ ). (C) The flow cytometry analysis (left) and mean fluorescence intensity (right) of MHC-II, CD40 and CD80 markers of DCs on different samples.  $n = 3$  biologically independent samples. Statistical analysis was performed using ANOVA comparison. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , and \*\*\*\* $p < 0.0001$ .



increased with time during the first 4 h. After 4 h of incubation, the correlation values of all CpG NPs were higher than the correlation threshold of 0.5, indicating the successful co-localization of CpG NPs and lysosomes.<sup>41</sup> To eliminate the influence of fluorescence intensity changes on co-localization parameters, we then used the Manders' overlap as an indicator to assess the co-localization between CpG NPs and lysosomes. It ranges from 0 to 1; zero correlates to no overlap and one correlates to complete overlap. As shown in Fig. 2F, after incubation for 4 h, the co-localization levels between CpG NPs and lysosomes were significantly higher than that between free CpG ODNs and lysosomes. Thus, we speculate that the self-assembled CpG NPs may facilitate immune activation *via* enhancing cell internalization and interaction with TLR9 on lysosome membranes.

### 3.3. Innate immune responses of CpG NPs


To evaluate the immune potency of the prepared CpG NPs, we detected and compared the innate immune response levels induced by CpG ODNs and CpG NPs. First, we incubated RAW264.7 macrophages with the safe dose (1000 nM) of CpG ODNs and CpG NPs for 20 h and then tested mRNA expression levels of their secreted proinflammatory cytokines. As shown in Fig. 3A, after treatment with CpG NPs, the expression levels of tumor necrosis factor (TNF)- $\alpha$  and interleukin (IL)-12b secreted by RAW264.7 macrophages were significantly higher than those of untreated cells. As the typical markers of inflammatory macrophages (M1 phenotype), expression levels of TNF- $\alpha$  and IL-12b represent levels of immune activation. In comparison to cells treated with free CpG and free FeCl<sub>2</sub>, CpG NP treated cells secreted more proinflammatory cytokines. This is probably caused by the stronger pro-inflammatory interaction due to the enhanced uptake amount of CpG NPs into cells compared with free CpG. Additionally, NP<sup>po</sup>-treated cells secreted the most amount of TNF- $\alpha$  and IL-12b, which was beyond 10 and 15 times that of untreated cells, respectively. This is consistent with the above cellular uptake results. Considering the immunosuppressive microenvironment in tumors, we next analyzed macrophage polarization from the immunosuppressive M2 to the immunostimulatory M1 phenotype in the presence of free CpG, FeCl<sub>2</sub> and CpG NPs. Thus, RAW264.7 macrophages were pre-induced to differentiate into the M2 phenotype by IL-4. As revealed in Fig. 3B, after cells were treated with 10 ng mL<sup>-1</sup> IL-4 for 20 h, the gene expression levels of arginase (Arg)-1 and mannose receptor C type 1 (Mrc-1) were dramatically increased, indicating their successful differentiation into the M2 phenotype. As expected, a noticeable up-regulation of proinflammatory cytokine (TNF- $\alpha$  and IL-12b) expression was detected after stimulation with our CpG NPs for another 20 h. The expression levels of M2 markers (Arg-1 and Mrc-1) were also tested, showing their over 95% inhibition after incubation with CpG NPs (Table S4†). These results demonstrated that our designed CpG NPs can facilitate macrophage polarization from the immunosuppressive M2 to the immunostimulatory M1 phenotype, and their immune activation potency increased with the increased amount of cellular uptake.

Dendritic cells (DCs) present the broadest range of foreign antigens to T cells. Once the NPs are internalized by DCs, it will induce the maturation of DCs and present them to naive helper CD4<sup>+</sup> T cells and naive cytotoxic CD8<sup>+</sup> T cells in immune organs and then activate them.<sup>42,43</sup> Thus, the expression levels of the surface markers of mature DCs, major histocompatibility complex class II (MHC-II), CD40 and CD80, were tested *via* flow cytometry. After incubation with different samples at a concentration of 1000 nM, NP<sup>po</sup>-treated DCs displayed extremely high mean fluorescence intensity (MFI) of MHC-II, CD40 and CD80 compared to those treated with other samples (Fig. 3C). This was probably caused by their enhanced cellular uptake amount. This data indicated that self-assembled CpG NPs with specific surface topography can significantly facilitate the maturation of DCs, thereby promoting the presentation of antigen by activated DCs to naive T cells. Together, our results suggested that the innate immune response was successfully amplified by regulating the surface topography of CpG NPs.

### 3.4. CpG NPs as a potent adjuvant for enhanced immunotherapy

To investigate the therapeutic efficacy of the CpG NPs as adjuvants of tumor antigens, melanoma-bearing mice were adopted to evaluate the ability of the prepared CpG NPs to inhibit tumor growth. Mice were first subcutaneously inoculated with B16-OVA cells for the construction of a melanoma cancer model. When the tumor volume reached *ca.* 100 mm<sup>3</sup>, free CpG, FeCl<sub>2</sub>, and CpG NPs were mixed with OVA model antigen and injected intramuscularly into the melanoma-bearing mice every 5 days, respectively. Tumor volumes were monitored every certain day as described in Fig. 4A. After a 17-day test, ratios of recruited mature DCs, activated T cells and natural killer (NK) cells in melanoma in different treatment groups were detected by flow cytometry. Gating strategies for them are shown in Fig. S9–S11.† Analysis of DC maturation showed no obvious difference among the experimental groups, except for a slight up-regulation induced by NP<sup>po</sup> (Fig. 4B). NK cells are an essential component in the removal of tumors. As shown in Fig. 4C and D, in contrast with free CpG and FeCl<sub>2</sub> treated groups, the numbers of activated KLRG1<sup>+</sup> NK cells and CD69<sup>+</sup> NK cells were greatly enhanced through the treatment of CpG NPs combined with OVA. Specifically, the percentage of KLRG1<sup>+</sup> NK cells was separately raised from 38.3% in the PBS-treated group to 79.6%, 67.7%, 83.8% and 79.4% in the four CpG NPs-treated groups. Similarly, the percentage of CD69<sup>+</sup> NK cells was separately raised from 26.7% in the PBS-treated group to 76.9%, 65.1%, 83.6% and 78.4% in the four CpG NP-treated groups. In addition, the NP<sup>po</sup>-treated group had the highest fold increase with more than two- and three-fold increases in the number of the two NK cells, individually. Regarding activated T cells, CD3<sup>+</sup>CD8<sup>+</sup> T cells were significantly increased in NP<sup>ur</sup>, NP<sup>po</sup>, and NP<sup>bu</sup>-treated groups, but there were no obvious changes in PBS, free CpG, free FeCl<sub>2</sub> and NP<sup>sp</sup>-treated groups (Fig. 4E). Similarly, melanoma-bearing mice treated with NP<sup>po</sup> and OVA revealed the highest percentage of activated T cells, about two-fold higher than that by the PBS, OVA plus free CpG, FeCl<sub>2</sub> or






**Fig. 4** Anti-tumor efficacy by the intramuscular injection of four structural CpG NPs on a melanoma model. (A) Schematic illustration of mice subcutaneously inoculated with B16-OVA cells for tumor modeling first, followed by intramuscular injection of PBS, free CpG, free FeCl<sub>2</sub>, or CpG NPs. Ratios of the tumor-infiltrating (B) DC maturation, (C) KLRG1<sup>+</sup> NK cells, (D) CD69<sup>+</sup> NK cells, and (E) CD8<sup>+</sup> T cells in the melanoma tumors upon various treatments. (F) The tumor volumes of mice with different treatments.  $n = 6$  biologically independent samples. (G) The significance between the indicated groups on days 4–17 was calculated by one-way ANOVA and is shown as a heat map. Data are presented as the mean  $\pm$  SD. NS, not significant.

NP<sup>sp</sup> treated groups and 1.5-fold higher than that by the OVA plus NP<sup>ur</sup> or NP<sup>bu</sup> treated groups. Finally, as illustrated in Fig. 4F, the injection of OVA and NP<sup>po</sup> almost completely blocked the tumor growth, whereas other treatment groups were much less effective. The immunotherapeutic benefit of OVA and NP<sup>po</sup> was evident as early as 10 days after intramuscular injection and continued throughout the entire experimental period (Fig. 4G). In conclusion, NP<sup>po</sup> synergistically worked with OVA to effectively promote DC maturation, activate NK cells and T cells in the tumor site, and inhibit tumor growth in melanoma-bearing mice.

### 3.5. Biosafety evaluation

To evaluate the clinical relevance of the prepared CpG NPs, their *in vivo* biosafety was assessed in healthy mice with the administration of immunostimulatory doses (10  $\mu$ g per mouse, 3.3  $\mu$ M equivalent CpG strands). Beforehand, the reactive oxygen species (ROS) in human immortalized keratinocytes (Hacat) were measured because the presence of ferrous ions would generate hydroxyl radicals ( $\cdot$ OH) in a weakly acidic microenvironment.<sup>44–47</sup> Hacat was incubated with free CpG, free FeCl<sub>2</sub>, and CpG NPs (CpG equivalent of 1000 nM) for 24 h. As



**Fig. 5** *In vivo* biosafety evaluation of the four structural DNA nanoparticles. (A) Schematic illustration of mice intramuscularly injected with PBS, free CpG, free FeCl<sub>2</sub>, and CpG NPs for a periodical test. (B) The body weight of the mice after injection of different samples tested on days 1, 4, 6, 8 and 10. (C) Histopathological analysis of major organs (heart, liver, spleen, lung and kidney) of mice on day 10 post-injection. (D) After a 10-day test, mouse spleens were removed and then ground to detect immune indicators. Before this, the removed spleens of mice with individual treatments were photographed (top) and weighed (bottom). (E) The assessment of DC maturation after various treatments (PBS, free CpG, free FeCl<sub>2</sub>, and the four types of CpG NPs) by staining with CD11b, CD80 and CD86 and then analyzed by flow cytometry. (F) The statistical analysis of the percentages of mature DCs, activated CD8<sup>+</sup> T cells (TCM and TEM), CD4/CD8 molecules on the surface of T cells, and IFN- $\gamma$  secreted from the CD8<sup>+</sup> T cells. All data are presented as mean  $\pm$  SD ( $n = 3$ ). I.M. injection, intramuscular injection.

shown in Fig. S12,† there was a relatively obvious increase in ROS levels in cells incubated with free FeCl<sub>2</sub> and four CpG NPs, ranging from 13 500 to 15 000. Taking the average ROS level (11 320) of PBS-treated cells as a control group, the ROS levels of free FeCl<sub>2</sub>-treated cells increased by 33.0% and those of four CpG NPs-treated cells increased by 19.5%, 27.3%, 30.6%, and

19.5%, respectively. The lower ROS levels of Hacat incubated with CpG NPs indicated controllable ROS and low ferroptosis probability in normal cells.

To further assess the *in vivo* biosafety of CpG NPs, healthy mice were intramuscularly injected with PBS, free CpG, free FeCl<sub>2</sub>, and self-assembled CpG NPs with an equivalent dose of

CpG strands (Fig. 5A). The body weight of mice was monitored after injection. As shown in Fig. 5B, the weight of mice in the experimental groups and the control group exhibited the same trend. All the mice continued to gain weight during the first six days and then lost a little. Ten days after injection, major organs (heart, liver, spleen, lung and kidney) were sectioned and stained for histopathological analysis. As displayed in Fig. 5C, hematoxylin and eosin (H&E) stained histologic sections of mice treated with free CpG, free FeCl<sub>2</sub>, or CpG NPs showed no difference from those treated with PBS. Moreover, there was no significant difference between each group in the spleen weight (Fig. 5D). The spleen, as the largest immune organ, contains a large number of immune cells. It is the genesis center of cellular immunity and humoral immunity and plays an important role in anti-tumor efficacy. Therefore, mouse spleens were subsequently ground for immunological analysis to further evaluate the systematic immune safety of CpG NPs. Activation markers expressed on the cell membrane, such as CD11b, CD80, and CD86 secreted by DCs and CD3, CD4, CD8, and IFN- $\gamma$  secreted by T cells were determined by flow cytometry based on the gating strategies shown in Fig. S13–S15<sup>†</sup>. As depicted in Fig. 5E, the average percentage of mature DCs increased from 15.9% in the PBS-treated group to 19.7%, 18.4%, 21.3% and 22.0% in the free CpG, NP<sup>SP</sup>, NP<sup>PO</sup> and NP<sup>bu</sup>-treated groups, respectively. The proportion of mature DCs was marginally reduced in the other two groups. These negligible changes indicated that CpG NPs have no adverse effect on the immune system of healthy mice. As for activated T cells, except for NP<sup>PO</sup>, no distinct changes can be observed in other groups. As shown in Fig. 5F, the percentages of central memory T cells (TCM), effector memory T cells (TEM) and interferon-gamma (IFN- $\gamma$ ) in the spleen of NP<sup>PO</sup>-treated mice increased slightly and remained below 20%, 40% and 6%, respectively; the percentages of CD4 and CD8 molecules on the surface of T cells decreased by 7.3 and 4.1%, respectively. Overall, CpG NPs have no adverse effects associated with autoimmune toxicity or systemic toxicities. These results declared the good biosafety of the prepared CpG NPs, providing their potential as therapeutic vaccine adjuvants for effective tumor immunotherapy.

## 4. Conclusions

In summary, we successfully constructed CpG NPs with tunable surface topographies by regulating the co-assembly conditions between CpG ODNs and ferrous ions. Compared to free CpG ODNs, the assembled CpG NPs exhibited enhanced cellular uptake behaviors and amplified innate immune responses (macrophage polarization and DC maturation). Significantly, CpG NPs with a pompon-shaped nanostructure (NP<sup>PO</sup>) showed higher cellular uptake efficiency and immunostimulatory capacity than other nanostructures. Furthermore, when combined with the tumor model antigen—OVA, NP<sup>PO</sup> showed the strongest anti-tumor efficacy on a B16-OVA melanoma-bearing mouse model, indicating the desired surface topography for an optimal adjuvant effect. Ultimately, *in vitro* and *in vivo* systematic toxicity assays indicated the favorable safety of the CpG NPs for biological applications. Together, this study

demonstrated that CpG NPs with specific surface topography highly amplified the immune activation performance of the TME, which holds great promise as an effective immunological adjuvant in cancer therapy.

## Author contributions

Li Zhang: investigation, methodology, validation, formal analysis, data curation, visualization, writing – original draft. Lingpu Zhang: investigation, methodology, validation, formal analysis, data curation, visualization. Yuqi Wang: investigation, resources, writing – review & editing, visualization. Kai Jiang: investigation, resources. Chao Gao: investigation, resources. Pengfei Zhang: writing – review & editing, visualization. Yujie Xie: writing – review & editing, visualization. Bin Wang: writing – review & editing, visualization. Haihua Xiao: resources, writing – review & editing, visualization, supervision. Jie Song: conceptualization, methodology, resources, writing – review & editing, supervision, project administration, funding acquisition.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors are grateful for the financial support from the National Natural Science Foundation of China (No. 22161132008) and the National Key R&D Program of China (No. 2021YFF1200200 and 2022YFA1304500).

## Notes and references

- 1 M. J. Lin, J. Svensson-Arvelund, G. S. Lubitz, A. Marabelle, I. Melero, B. D. Brown and J. D. Brody, *Nat. Cancer*, 2022, **3**, 911–926.
- 2 A. York, *Nat. Rev. Cancer*, 2021, **21**, 214–215.
- 3 J. D. Martin, H. Cabral, T. Stylianopoulos and R. K. Jain, *Nat. Rev. Clinic. Oncol.*, 2020, **17**, 251–266.
- 4 J. Meng, P. Zhang, Q. Chen, Z. Wang, Y. Gu, J. Ma, W. Li, C. Yang, Y. Qiao and Y. Hou, *Adv. Mater.*, 2022, **34**, 2202168.
- 5 S. Liu, Q. Jiang, X. Zhao, R. Zhao, Y. Wang, Y. Wang, J. Liu, Y. Shang, S. Zhao, T. Wu, Y. Zhang, G. Nie and B. Ding, *Nat. Mater.*, 2021, **20**, 421–430.
- 6 B. Zhou, J. Liu, M. Lin, J. Zhu and W. R. Chen, *Coordin. Chem. Rev.*, 2021, **442**, 214009.
- 7 B. Pulendran, S. A. P and D. T. O'Hagan, *Nat. Rev. Drug Discovery*, 2021, **20**, 454–475.
- 8 L.-X. Zhang, J. Hu, Y.-B. Jia, R.-T. Liu, T. Cai and Z. P. Xu, *Nanoscale*, 2021, **13**, 7533–7549.
- 9 Y. Li, C. Ayala-Orozco, P. R. Rauta and S. Krishnan, *Nanoscale*, 2019, **11**, 17157–17178.
- 10 J. Ming, J. Zhang, Y. Shi, W. Yang, J. Li, D. Sun, S. Xiang, X. Chen, L. Chen and N. Zheng, *Nanoscale*, 2020, **12**, 3916–3930.



11 R. Khalifehzadeh and H. Arami, *Nanoscale*, 2020, **12**, 9603–9615.

12 G. Del Giudice, R. Rappuoli and A. M. Didierlaurent, *Semin. Immunol.*, 2018, **39**, 14–21.

13 N. Hanagata, *Int. J. Nanomed.*, 2017, **12**, 515–531.

14 S. R. Paludan and A. G. Bowie, *Immunity*, 2013, **38**, 870–880.

15 A. M. Krieg, *Curr. Opin. Immunol.*, 2000, **12**, 35–43.

16 R. N. Hyer and R. Janssen, *Open Forum Infect. Dis.*, 2018, **5**, S677–S678.

17 S. Schillie, A. Harris, R. Link-Gelles, J. Romero, J. Ward and N. Nelson, *Morb. Mortal. Wkly. Rep.*, 2018, **67**(15), 455.

18 M. H. Teplensky, M. Evangelopoulos, J. W. Dittmar, C. M. Forsyth, A. J. Sinegra, S. Wang and C. A. Mirkin, *Nat. Biomed. Eng.*, 2023, 1–17.

19 H. Shan, W. Dou, Y. Zhang and M. Qi, *Nanoscale*, 2020, **12**, 22268–22280.

20 X. Dong, J. Liang, A. Yang, Z. Qian, D. Kong and F. Lv, *Biomaterials*, 2019, **209**, 111–125.

21 J. Zhou, L. Sun, L. Wang, Y. Liu, J. Li, J. Li, J. Li and H. Yang, *Angew. Chem., Int. Ed. Engl.*, 2019, **58**, 5236–5240.

22 S. Zhang, Y. Feng, M. Meng, Z. Li, H. Li, L. Lin, C. Xu, J. Chen, K. Hao and Z. Tang, *Biomaterials*, 2022, **289**, 121794.

23 A. Banstola, J.-H. Jeong and S. Yook, *Acta biomater.*, 2020, **114**, 16–30.

24 J. Tan, B. Ding, B. Teng, P. a. Ma and J. Lin, *Adv. Funct. Mater.*, 2022, **32**, 2111670.

25 J. Li, X. Jiang, H. Li, M. Gelinsky and Z. Gu, *Adv. Mater.*, 2021, **33**, 2004172.

26 Y. Zhu, H. Liang, X. Liu, J. Wu, C. Yang, T. M. Wong, K. Y. Kwan, K. M. Cheung, S. Wu and K. W. Yeung, *Sci. Adv.*, 2021, **7**, eabf6654.

27 J. Wang, H. J. Chen, T. Hang, Y. Yu, G. Liu, G. He, S. Xiao, B. R. Yang, C. Yang, F. Liu, J. Tao, M. X. Wu and X. Xie, *Nat. Nanotechnol.*, 2018, **13**, 1078–1086.

28 S. N. Christo, A. Bachhuka, K. R. Diener, A. Mierczynska, J. D. Hayball and K. Vasilev, *Adv. Healthcare Mater.*, 2016, **5**, 956–965.

29 A. Chen, L. Wu, Y. Luo, S. Lu, Y. Wang, Z. Zhou, D. Zhou, Z. Xie and J. Yue, *Small*, 2022, **18**, 2200993.

30 L. Xu, X. Wang, W. Wang, M. Sun, W. J. Choi, J. Y. Kim, C. Hao, S. Li, A. Qu, M. Lu, X. Wu, F. M. Colombari, W. R. Gomes, A. L. Blanco, A. F. de Moura, X. Guo, H. Kuang, N. A. Kotov and C. Xu, *Nature*, 2022, **601**, 366–373.

31 L. A. Dykman, S. A. Staroverov, A. S. Fomin, V. A. Khanadeev, B. N. Khlebtsov and V. A. Bogatyrev, *Int. Immunopharmacol.*, 2018, **54**, 163–168.

32 K. Lee, Z. N. Huang, C. A. Mirkin and T. W. Odom, *Nano Lett.*, 2020, **20**, 6170–6175.

33 M. Li, C. Wang, Z. Di, H. Li, J. Zhang, W. Xue, M. Zhao, K. Zhang, Y. Zhao and L. Li, *Angew. Chem., Int. Ed. Engl.*, 2019, **58**, 1350–1354.

34 J. Zhang, Z. Di, H. Yan, Y. Zhao and L. Li, *Nano Lett.*, 2021, **21**, 2793–2799.

35 H. Sigel, *Biol. Trace Elem. Res.*, 1989, **21**, 49–59.

36 H. Sigel and R. Griesser, *Chem. Soc. Rev.*, 2005, **34**, 875–900.

37 F. R. Steven Daly and V. Gabelica, *Science*, 2020, **368**, 1465–1468.

38 B. Ranjbar and P. Gill, *Chem. Biol. Drug Des.*, 2009, **74**, 101–120.

39 U. Ohto, T. Shibata, H. Tanji, H. Ishida, E. Krayukhina, S. Uchiyama, K. Miyake and T. Shimizu, *Nature*, 2015, **520**, 702–705.

40 D. M. Klinman, *Nat. Rev. Immunol.*, 2004, **4**, 249–258.

41 K. W. Dunn, M. M. Kamocka and J. H. McDonald, *Am. J. Physiol. Cell Physiol.*, 2011, **300**, C723–C742.

42 S. K. Wculek, F. J. Cueto, A. M. Mujal, I. Melero, M. F. Krummel and D. Sancho, *Nat. Rev. Immunol.*, 2020, **20**, 7–24.

43 R. L. Sabado, S. Balan and N. Bhardwaj, *Cell Res.*, 2017, **27**, 74–95.

44 H. Ranji-Burachaloo, P. A. Gurr, D. E. Dunstan and G. G. Qiao, *ACS Nano*, 2018, **12**, 11819–11837.

45 Z. Tang, Y. Liu, M. He and W. Bu, *Angew. Chem., Int. Ed. Engl.*, 2019, **58**, 946–956.

46 Z. Tang, P. Zhao, H. Wang, Y. Liu and W. Bu, *Chem. Rev.*, 2021, **121**, 1981–2019.

47 F. Zhang, F. Li, G. H. Lu, W. Nie, L. Zhang, Y. Lv, W. Bao, X. Gao, W. Wei, K. Pu and H. Y. Xie, *ACS Nano*, 2019, **13**, 5662–5673.

